The experts of the Food and Drug Administration (FDA) have not taken a clear position on whether or not the US regulatory agency authorizes a booster dose of the anti-Covid vaccine developed by Moderna. This is what emerges from a report published in view of a 2-day meeting called by the FDA on the recalls of the Moderna and Johnson & Johnson vaccines, and the news was reported by the American media.
According to experts, the data do not demonstrate the need to administer a third dose of Moderna vaccine, a booster for which the company has asked for the green light at a halved dosage, to be administered at least 6 months after the conclusion of the primary immunization cycle.
“Some real-world efficacy studies have suggested a decrease in the efficacy of the Moderna vaccine against Covid-19 over time against symptomatic infection or the Delta variant, while others have not,” the FDA experts wrote.